Aggressive Surgery for Pancreatic Neuroendocrine Tumors Abstract #766

Introduction: The role of surgery for advanced pancreatic neuroendocrine tumor (pNET) requiring extended resections is not well-defined.
Aim(s): To clarify whether aggressive surgical approach influenced long-term results and to identifiy survival prognostic factors in light of the 2010 WHO classification.
Materials and methods: Between 01/2000 and 03/2012, 37 patients with pNET underwent pancreatic resection alone (Group I:27 patients) or associated to extended resection (Group II:10 patients). All tumors were reclassified according to the 2010 WHO classification.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: Nadia Russolillo

To read results and conclusion, please login ...

Further abstracts you may be interested in

#769 Surgicial Management of Gastroenteropancreatic Neuroendocrine Tumors: Early and Long-Term Results
Introduction: Surgery could improve survival of gastroenteropancreatic neuroendocrine tumors (GEP NET). Nevertheless, data on survival prognostic factors come from studies focusing on heterogeneous population including both resected and non-resected patients.
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: Nadia Russolillo
Keywords: GEP-NET, surgery
#1144 Aggressive Multi-Modality Treatment of Pancreatic Neuroendocrine Tumors (pNETs): Outcomes in Patients with Advanced Disease
Introduction: pNETs carry the worst prognosis of all NETs, particularly when hepatic metastasis are present. We try to actively treat all patients referred.
Conference: 12th Annual ENETS Conference (2015)
Category: Surgical treatment
Presenting Author: Damian Mayo
Authors: Mayo D, Armstrong T, Cave J, Nolan L, ...
#497 Metastatic Pancreatic Neuroendocrine Carcinoma: Does Aggressive Surgical Intervention Improve Outcome?
Introduction: Pancreatic neuroendocrine tumors (PNETS) often present late. At diagnosis, 65% of patients have metastases, with median survival of 24 months. The conventional approach is conservative management. Recent evidence has suggested that aggressive treatment leads to better outcomes.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Michael White
Keywords: pancreatic, surgery
#83 Surgical treatment of duodenopancreatic neuroendocrine tumors (pNETs) in patients with multiple endocrine neoplasia type 1 (MEN 1): a Dutch consensus statement
Introduction: Duodenopancreatic neuroendocrine tumors (pNETs) in multiple endocrine neoplasia type 1 (MEN 1) are the most important cause of MEN 1-related death. Surgery is the only curative treatment, but controversy exists on the optimal strategy. Recent guidelines on pNETs have limited recommendations specific for MEN 1. Therefore, a Dutch multidisciplinary consensus meeting was organized.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Carolina RC Pieterman
#701 High Expression of Mammalian Target of Rapamycin (mTOR) in NF1-Related Periampullary Neuroendocrine Tumors
Introduction: Neurofibromatosis type 1 (NF1) is a rare inherited disorder associated with cutaneous lesions and neoplasms in the nervous and gastroenteropancreatic systems, including periampullary NETs. NF1-coded protein, neurofibromin, is a tumor suppressor that negatively regulates the mammalian target of rapamycin (mTOR). Preclinical in vitro and in vivo studies demonstrated a constitutive activation of mTOR pathway associated with significant antineoplastic effects of mTOR inhibitors in NF1-related glial tumor models.
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: MD Paola Razzore